The Charcot-Marie-Tooth Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Charcot-Marie-Tooth Disease. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued products.

GlobalData tracks 50 drugs in development for Charcot-Marie-Tooth Disease by 42 companies/universities/institutes. The top development phase for Charcot-Marie-Tooth Disease is preclinical with 28 drugs in that stage. The Charcot-Marie-Tooth Disease pipeline has 42 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Charcot-Marie-Tooth Disease pipeline products market are: Recursion Pharmaceuticals, Bristol-Myers Squibb and Novartis.

The key targets in the Charcot-Marie-Tooth Disease pipeline products market include Peripheral Myelin Protein 22 (Growth Arrest Specific Protein 3 or GAS3 or PMP22), Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid (GABA) B Receptor or GABBR).

The key mechanisms of action in the Charcot-Marie-Tooth Disease pipeline product include Peripheral Myelin Protein 22 (Growth Arrest Specific Protein 3 or GAS3 or PMP22) Inhibitor with nine drugs in Preclinical. The Charcot-Marie-Tooth Disease pipeline products include five routes of administration with the top ROA being Oral and nine key molecule types in the Charcot-Marie-Tooth Disease pipeline products market including Small Molecule, and Gene Therapy.

Charcot-Marie-Tooth Disease overview

Charcot-Marie-Tooth disease (CMT) is a term for a group of inherited genetic disorders that affect the peripheral nerves, which connect the brain and spinal cord to the muscles and sensory organs. CMT causes progressive weakness, muscle wasting, and loss of sensation in the feet, legs, hands, and arms. It can also cause foot deformities such as high arches or flat feet. CMT usually begins in childhood or early adulthood, but symptoms can vary widely in severity and onset. There is no cure for CMT, but treatments can help manage the symptoms and maintain function.

For a complete picture of Charcot-Marie-Tooth Disease’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.